Framingham, Mass.– TheracosBio has partnered with Publix pharmacies to make its FDA-approved diabetes drug BRENZAVVY® (bexagliflozin) available at a significantly reduced price, in a move aimed at improving access to treatment for patients with type 2 diabetes.
The drug, part of the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, is now offered across more than 1,400 Publix pharmacy locations in the Southeastern United States. For uninsured or cash-paying patients, BRENZAVVY is priced at about 90% less than comparable medications in the same class, according to the company.
“Many patients on fixed incomes struggle to afford consistent diabetes care,” said Brian Connelly, CEO of TheracosBio. “This collaboration with Publix is about offering a clinically effective, more affordable option.”
BRENZAVVY is a once-daily oral tablet that helps lower blood sugar levels in adults with type 2 diabetes. It is approved for use in patients with an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m² or higher, including those in stage 3 chronic kidney disease. Clinical trials have shown the medication reduces hemoglobin A1c and fasting glucose levels both as a standalone treatment and when used alongside other diabetes therapies.
While not approved for weight loss or blood pressure reduction, some patients in clinical studies experienced modest improvements in both areas.
The partnership reflects a growing push to make essential medications more accessible amid rising healthcare costs, particularly in chronic disease management.
